SPR206

SPR206 is a novel, next-generation polymyxin derivative developed for intravenous administration to treat serious infections caused by multidrug-resistant (MDR) Gram-negative bacteria, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Escherichia coli*, and *Enterobacter* species. It acts by interacting with the **bacterial outer membrane** to exert its antibacterial effects. Compared to older polymyxins like polymyxin B and colistin, SPR206 demonstrates potent *in vitro* and *in vivo* activity against MDR pathogens with a potentially improved safety profile—particularly reduced nephrotoxicity. Clinical studies have shown that SPR206 is generally well tolerated at therapeutic doses without significant kidney toxicity. The drug is being developed primarily for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), both of which are often caused by drug-resistant Gram-negative organisms.

Other names

EVER206EVER-206EVER 206SPR206SPR-206SPR 206